TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction of DH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of HPV-related cervical intraepithelial neoplasia grade 2/3 and other related conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: hemodynamic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: venous return enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDD remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of segments with attenuation of at least 300 HU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of median daily ICS dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of liver function markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fibrous tissue in the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of appointments required for preventive dental care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attack count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum attack duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar formation
Endpoint domain: Adverse events/effects
Primary endpoint: Hyperpigmentation rate
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of cardio‐cerebral vascular events
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of postoperative thirst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in nasal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with neutrophils 1+ to 3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects with mast cells >1+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: insulin-lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent of patients alive at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in the appearance of atrophic scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean change in KOOS(4) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS-III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean aqueous level of topical levofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unsafe behavior while waiting
Endpoint domain: Adverse events/effects
Primary endpoint: Unsafe behavior during boarding
Endpoint domain: Adverse events/effects
Primary endpoint: estimated intraoperative blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: narcotic requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of the first target (T1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitudes of the P2 and P3 components of the event‐related potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pelvic floor muscle function (MVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of liver metastases
Endpoint domain: Mortality/survival
Primary endpoint: number of metastatic sites
Endpoint domain: Mortality/survival
Primary endpoint: clinically significant pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion resolution rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 AUC0‐3 and trough FEV1 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean peak log₁₀ viral titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of primary composite outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Implementation of the discontinuation letter
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of eyes with 20/20 or better acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean postoperative spherical equivalent (SE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes within +/-0.50 D of emmetropia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score on the Functional Outcomes of Sleep Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: respiratory system compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain of cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of mood symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteopenia risk
Endpoint domain: Adverse events/effects
Primary endpoint: risk of nephrotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Combined early morbidity rate (TIA, stroke, and >or=50% restenosis or thrombosis)
Endpoint domain: Adverse events/effects
Primary endpoint: Breast-milk magnesium secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: total exposure (AUC0→t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of postoperative bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of stretch sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in lumbar neural tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 month death
Endpoint domain: Mortality/survival
Primary endpoint: reduction in median low density lipoprotein (LDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increase in endothelial progenitor cells‐colony forming unit (EPC‐CFU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of complete fibroid resections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: C-reactive protein (CRP) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin-6 (IL-6) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Likelihood of being offered active treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sick Absence (SA) days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of high Sick Absence (SA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to virus negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to bruise resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bruise severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tobacco abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: craving levels
Endpoint domain: Adverse events/effects
Primary endpoint: ALT aggregation with components of MetS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase in dermal thickness (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of core cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary aspiration
Endpoint domain: Adverse events/effects
Primary endpoint: repeat sprint performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total blood loss from the drain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: pre‐ and postoperative hemoglobin difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Norepinephrine dose decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of emesis
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygen desaturation after suctioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postprandial antral pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adjusted change in HSDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted change in BMI SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychopathological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 120- to 180-minute Rd values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Death of any cause up to 30 days after randomization
Endpoint domain: Mortality/survival
Primary endpoint: Severity of cardiac pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: practical examination score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of subjects found to have 1 or more adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportions of subjects found to have advanced adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportions of subjects found to have clinically significant serrated polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in gastrointestinal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in daily episodes of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in intensity of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: DQ value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-adenosine LV ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fasting glycogen values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: success rate of oxygen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: partial pressure of arterial oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: discomfort related to interface displacement and airway dryness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: aversive emotional response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of new sensitizations
Endpoint domain: Adverse events/effects
Primary endpoint: Contrast enhancement of abdominal vessels and organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily function (FOSQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Concentrations of androgens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adverse effects (somnolence and nausea)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of meals consumed per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: homework completion
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: mother-reported treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: delayed composite memory score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strategy use in everyday life
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: clinical resolution of diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in synovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in osteitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset and offset of sensory and motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: demand for intraoperative anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative analgesia request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast cancer treatment-related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction or resolution of pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: central nervous system side effects of perphenazine
Endpoint domain: Adverse events/effects
Primary endpoint: MaxZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIT concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean change in BCVA (ETDRS letters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with any single postdose intraocular pressure ≥30 mmHg
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with glaucoma
Endpoint domain: Adverse events/effects
Primary endpoint: nodule volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EF domain score in the normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in EF domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to thrombosis
Endpoint domain: Mortality/survival
Primary endpoint: Significant complications from thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Time to complete uterine incision repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: amount of hemorrhage in hemovac drains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: full-scale IQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of poor outcomes (death or severe disability)
Endpoint domain: Mortality/survival
Primary endpoint: functional limitations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postural capacity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional improvement in ACFAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Withdrawal syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement for buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No-flow time (NFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: colonic bubble score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnostic quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic confidence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of examinations rated as diagnostic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of erroneous answers at the multiple-choice questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in semiquantitative indexes of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in experienced pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: job task performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Concentrations of blood neutrophils and monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Phagocytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma IL‐1ra concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Local recurrence free survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of leukocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of liver dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: mean numbers of gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence, spectrum, and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of PBHs per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of arrhythmic death or cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: Duration of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term risk perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of anti-hypertensive medications used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in DSM-IV ADHD-RS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cigarettes per day during the post-quit phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of primary outcome in apixaban-treated patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of principal safety outcome in apixaban-treated patients
Endpoint domain: Adverse events/effects
Primary endpoint: intention to visit the website
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: likelihood of clicking on the link
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of pages visited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cardiac event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: LVdP/dt(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of the OT for diagnosing GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the OT for diagnosing GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: menstrual frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: worst sprint time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total sprints time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: swimming velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioural working memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: TWSNOT-20 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: saccharin transit times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Deep paratendon blood flow decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postcapillary venous filling pressures reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: total health care-related costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ease of preparation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of unsatisfactory preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% pain reduction within 30 min of drug administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of PCF formation
Endpoint domain: Adverse events/effects